Guardant Health
Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug
The companies will jointly develop and commercialize Guardant360 CDx and Guardant360 TissueNext for taletrectinib treatment in advanced and metastatic NSCLC.
Guardant Health Nabs FDA Approval for Liquid Biopsy CDx With Menarini Breast Cancer Drug
The firm's liquid biopsy assay Guardant360 CDx can now be used to identify patients eligible for treatment with Menarini's Orserdu in ESR1-mutant breast cancer.
Guardant Health Lays off 7 Percent of Workforce
In a statement, Guardant Health cited the need to balance innovation with "financial discipline and focused execution" in the current economic environment.
Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer
The study is evaluating the Guardant Reveal assay to guide chemotherapy treatment decisions following surgery for stage II to III colorectal cancer.
JP Morgan Healthcare Conference, Day 1: Guardant Health, Exact Sciences, Bruker, 10x Genomics, More
Highlights from the first day included Exact Sciences' profitability forecast, an update on QuidelOrtho's integration, and Guardant Health's "quantum leap forward" with its "smart" liquid biopsy platform.